TORONTO--(BUSINESS WIRE)--The 2021 OBIO Investment Summit national call for applications from health science companies that are seeking Series A or beyond investments is now open.
Taking place online February 9–10, 2021, the Summit will gather Canada’s most promising health science companies to present to and meet with top-ranked global investors. The Summit will also feature keynote presentations from world-leading scientific and business experts, including Dr. Michael Houghton, one of the recipients of the 2020 Nobel Prize in Physiology or Medicine.
“Building on the success of last year’s Summit, the 2021 OBIO Investment Summit will bring the most innovative Canadian health science companies together with leading global investors to create opportunities for new and cross-border investments,” said Gail Garland, President and CEO, OBIO. “With world-class technologies, leading-edge research and a great environment for investment, Canadian companies present an incredible opportunity for global health science investors. We are looking forward to bringing the world to Canada’s doorstep.”
“Last year Triumvira presented at the OBIO Investment Summit to great success. The Summit provided an important opportunity for us to showcase our innovation to new investors and allowed us to have key follow-up conversations from previous investor interactions,” said Christopher Helsen, Director Research and Development, Triumvira Immunologics.
In company presentations and one-on-one meetings, the Summit will highlight Canada’s most investable health sciences companies across therapeutic, medical device, diagnostic & digital health sectors.
Presentation spots are limited. Companies interested in presenting to investors should apply at obioinvestmentsummit.com. Companies must include a non-confidential investor pitch deck, demonstrating the company’s investor readiness and fit within the theme of the Summit.
The deadline for this round of applications is Thursday, November 26, 2020, at 11:59 PM EST. Applications will be reviewed by an expert Selection Committee and should demonstrate Series A (or higher) investment readiness. Companies are encouraged to apply early, since presentation spots are limited.
2021 OBIO Investment Summit Eligibility
- Companies with operations in Canada focused on developing health science products or services including but not limited to therapeutics, medical devices, diagnostics, or digital health which fit into the themes of the 2021 OBIO Investment Summit.
- Companies with operations in Canada seeking to raise Series A and beyond investment.
The Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health technologies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.